Finally, on pharmaceuticals, President Trump signed an executive order to fill the strategic Active Pharmaceutical Ingredients reserve so that America is never again caught flat footed when access to critical drug components is at risk. Last month, The White House also highlighted further action to impose tariffs on patented pharmaceutical products, while noting parallel section 232 Investigations involving personal protective equipment, medical consumable devices and robotics. The strategic message is unmistakable. Supply chain resilience in medicine will no longer be an afterthought. (11:19–11:36)
CLAIM
Asserts that tariffs on patented pharmaceutical products were imposed and investigations on medical equipment were noted.
This is an excerpt from a raw transcript. The assertions have not been audited or verified. Tap the video to view the source footage and understand the context.
